PATENT CLAIM ANALYSIS

Application Number: 16357918
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-09
Patent Classification: ["514", "04400A"]

Abstract:
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

Claim (Index 4):
A method for restoring an mRNA reading frame to induce dystrophin protein production in a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 45 skipping, comprising administering to the patient an antisense oligonucleotide of 22 bases in length, wherein the antisense oligonucleotide is 100% complementary to a target region of exon 45 of the human dystrophin pre-mRNA, wherein the target region is annealing site H45A(\u221203+19), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 45 skipping, or a pharmaceutically acceptable salt thereof, thereby restoring the mRNA reading frame to induce dystrophin protein production in the patient.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 99.0
- Lexical Diversity: 1.10345
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14944886', '14740097', '15661750', '14108137', '13509331']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8034414818116996
- 35 USC 102 Novelty (BERT): 0.7861109455140172
- Combined Prediction Score: 0.8017084281819313
- Mean Citation Score: 969.5078
- Max Citation Score: 1027.9857
- Similarity Product: 948.1162160620448

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test